Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 3 Undervalued Names Too Cheap to IgnoreWritten by Nathan Reiff. Article Posted: 3/7/2026. 
Article Highlights - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like a poor time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with valuation metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, such as compelling dividends or promising new product developments. While value opportunities can be harder to find when many promising companies are back in favor—or when apparent value hides deteriorating operations—well-established, stable names can still provide attractive prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works China just banned critical mineral exports to U.S. defense contractors, cutting off the materials inside every F-35, nuclear submarine, and hypersonic missile at the source—China controls 80-90% of processing and just weaponized it. The Trump administration escalated immediately with Executive Order 14285 declaring seabed minerals a national security priority, and now $20 trillion worth of nickel, cobalt, copper, and manganese sits in potato-sized rocks on the Pacific Ocean floor with one micro-cap company launching its strategy within five days of the rule change, led by a 25-year deepwater veteran and trading at ~C$26 million while the sector leader sits at ~$2.74 billion. Read the full intelligence briefing now Although shares have climbed more than 28% over the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year, and analysts see about 5% upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and generated about $8.4 billion in sales in Q4 2025, up nearly 7% year-over-year. Keytruda also shows promise in ovarian cancer, which could expand its patient base. Those factors should help Merck build revenue as it prepares for Keytruda's patent expiration in 2028. Merck's portfolio is broadening beyond oncology. The company recently reported notable phase 3 results for clesrovimab-cfor (branded Enflonsia), an RSV treatment for young children. At the same time, Merck is reconfiguring its human health organization—splitting it into two units—to more easily expand non-cancer drug sales as it looks beyond Keytruda. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen roughly 37% over the last year as the food-and-beverage staple has faced headwinds from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share fell about 13%. The company has not yet seen meaningful margin improvement after launching cost-saving initiatives. The near term is likely to remain challenging given weak fiscal-year guidance overall. Still, Campbell's improving supply-chain execution and strong brand loyalty—especially for its premium offerings—should provide some protection. A shifting tariff landscape could also alleviate part of the pressure the company faces. Importantly for income-oriented investors, Campbell's remains a notable dividend play, with an attractive yield of 5.9%, though its payout ratio is relatively high at over 80%. Campbell's current P/E of about 13.5 is the lowest in roughly four years. Those factors may convince some investors that the stock is worth considering despite Wall Street caution. A Recent US Foods Rally May Continue; Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has taken a different path from Campbell's—shares are up about 33% over the last year. Its reported P/E is 31.6. On the fundamentals, US Foods is making important strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year-over-year. Better inventory management and cost-of-goods savings are helping the firm gain traction. With a $4 billion capital deployment plan in place, US Foods appears well-positioned to sustain revenue momentum and continue improving adjusted EBITDA. Analysts rate USFD a Moderate Buy (11 Buys and 2 Holds) and see roughly 15% upside potential.
| 
